Trial Profile
A Phase I Study of Intravenous DX-8951f in Patients With Advanced Myelodysplastic Syndromes, Refractory Acute Leukemia, Refractory or Transformed Chronic Lymphocytic Leukemia, and Chronic Myelogenous Leukemia in Blastic Phase
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Exatecan (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 20 Feb 2024 Last checked against:ClinicalTrials.gov: US National Institutes of Health
- 15 Aug 2017 New trial record